Analysis
Exposing drug industry funding of UK patient organisations
BMJ 2019; 365 doi: https://doi.org/10.1136/bmj.l1806 (Published 22 May 2019) Cite this as: BMJ 2019;365:l1806Linked BMJ Opinion
Industry links with patient organisations—transparency is fundamental
Data supplement
Web extra
- Data Supplement - Web supplement 1: Search strategy
- Data Supplement - Web supplement 2: Disclosure reports published by ABPI and non-ABPI companies
- Data Supplement - Web supplement 3: Identification of payments to UK patient organisations
- Data Supplement - Web supplement 4: Timeline of data collection
- Data Supplement - Web supplement 5: Details of drug company payment disclosure reports
- Data Supplement - Web supplement 6: Details of payments
Related articles
- Analysis Published: 17 May 2018; BMJ 361 doi:10.1136/bmj.k1039
- Letter Published: 18 February 2019; BMJ 364 doi:10.1136/bmj.l740
- Editorial Published: 14 March 2017; BMJ 356 doi:10.1136/bmj.j1251
- Feature Published: 03 May 2007; BMJ 334 doi:10.1136/bmj.39185.461968.AD
- Analysis And Comment Published: 25 May 2006; BMJ 332 doi:10.1136/bmj.332.7552.1268
- Research Published: 18 August 2016; BMJ 354 doi:10.1136/bmj.i4189
- Research Published: 16 January 2019; BMJ 364 doi:10.1136/bmj.k5300
- Feature Published: 03 May 2007; BMJ 334 doi:10.1136/bmj.39185.394005.AD
- Editorial Published: 06 July 2016; BMJ 354 doi:10.1136/bmj.i3730
- AnalysisBetting on hepatitis C: how financial speculation in drug development influences access to medicinesPublished: 27 July 2016; BMJ 354 doi:10.1136/bmj.i3718
- News Published: 23 May 2019; BMJ 365 doi:10.1136/bmj.l2317
- Correction Published: 03 June 2019; BMJ 365 doi:10.1136/bmj.l2365
- Research Published: 12 December 2019; BMJ 367 doi:10.1136/bmj.l6694
- Research Published: 05 February 2020; BMJ 368 doi:10.1136/bmj.m7
See more
- Christopher MayersBMJ March 24, 2023, 380 p684; DOI: https://doi.org/10.1136/bmj.p684
- John Rizzo NaudiBMJ March 24, 2023, 380 p685; DOI: https://doi.org/10.1136/bmj.p685
- Social prescribing in the NHS—is it too soon to judge its value?BMJ March 24, 2023, 380 p699; DOI: https://doi.org/10.1136/bmj.p699
- W David S McLayBMJ March 24, 2023, 380 p691; DOI: https://doi.org/10.1136/bmj.p691
- Clare JonesBMJ March 24, 2023, 380 p682; DOI: https://doi.org/10.1136/bmj.p682
Cited by...
- 'Lines in the sand: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders
- Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations
- Pharmaceutical marketing--greater than the sum of its parts?
- Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
- Association between financial links to indoor tanning industry and conclusions of published studies on indoor tanning: systematic review
- "Asset exchange"--interactions between patient groups and pharmaceutical industry: Australian qualitative study
- Industry donated over {pound}57m to UK patient organisations from 2012 to 2016